Advancing Drug Development for the Prevention of Spontaneous Preterm Birth
January 23 & 24, 2024 • 1:00 – 4:30 PM • Virtual Public Workshop (Zoom)

Workshop Agenda

Day One | Current Landscape, Challenges, and Perspectives on Prevention of Spontaneous Preterm Birth

1:00 PM Welcome and Introduction

1:05 PM Opening Remarks from FDA

1:15 PM Session 1: Current Understanding of Spontaneous Preterm Birth
This session will highlight the impacts of spontaneous preterm birth and provide an overview of the epidemiology, etiologies, and pathophysiology of spontaneous preterm birth. There will be discussion of the current tools and methods used to predict spontaneous preterm birth and the progress made in recent years.

Moderated Discussion and Q&A

2:15 PM Session 2: Ethical and Regulatory Considerations and Challenges Associated with the Development of Therapeutics for Prevention of Spontaneous Preterm Birth
Experts will provide an overview of regulatory considerations, including the process of evaluating efficacy and safety of investigational products. The experts will discuss the ethical considerations used in clinical trials and the challenges to develop therapies for preterm birth.

Moderated Discussion and Q&A

3:15 PM Break

3:30 PM Session 3: Impact of Preterm Birth on Families and Society
This patient-focused session will discuss the short- and long-term challenges of caring for infants and children born preterm from the voices of parents and experienced clinicians, nurses, caregivers, and social workers.

Moderated Discussion and Q&A

4:30 PM Closing Remarks and Day One Adjournment

Adjourn
Day Two | Considerations for the Development of Therapies for the Prevention of Preterm Birth

1:00 PM Opening Remarks and Summary of Day 1

1:10 PM Session 4: Assessing Efficacy and Safety in Clinical Programs for Therapeutics for Spontaneous Preterm Birth Prevention
Experts will discuss the efficacy and safety assessments used in clinical programs as well as opportunities to improve and address the challenges within these programs. The discussion will consider how researchers can identify clinically relevant neonatal outcomes.

Moderated Discussion and Q&A

2:20 PM Break

2:35 PM Session 5: Dose-Finding and Clinical Trial Design Considerations
Field experts will discuss the importance of identifying a target drug for development and the data needed to support clinical trials for both novel and approved products, emphasizing consideration of different study populations and control groups in clinical trials. They will also discuss dose finding while considering physiologic changes in pregnancy and drug metabolism.

Moderated Discussion and Q&A

3:45 PM Wrap-up with Workshop Moderators (20 minutes)
Panel members will discuss the key takeaways from each session and provide next steps in advancing drug development for the prevention of preterm birth.

4:25 PM Closing Remarks and Meeting Adjournment

4:30 PM Adjourn

This workshop is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award [U19FD006602] totaling $4,241,714 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.